European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma

by Alex Weber
March 16, 2022
A A
Share on LinkedinShare on Twitter
  • Investment will accelerate the overall Sarclisa® development program
  • Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa® (isatuximab)

Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa®, to treat patients with multiple myeloma (MM). If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022.

For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company Enable Injections, Inc. to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment experience.

To-date, Sarclisa® has received regulatory approval for intravenous administration to treat certain patients with relapsed MM and is under investigation across the MM treatment continuum of care for other hematologic malignancies and solid tumors.

John Reed, MD, Ph.D., Global Head of Research and Development for Sanofi:
“The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient. We are committed to building an industry-leading, sustainable pipeline with a steady stream of new therapies that have the potential to transform the practice of medicine”.

Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences:
“We are excited to collaborate with Sanofi’s experienced development team to advance a subcutaneous dosage form for Sarclisa for patients. Our investment demonstrates Blackstone’s commitment and ability to provide innovative sources of financing to the world’s leading pharmaceutical companies as we offer capital at scale and complementary expertise to help advance important medicines in critical therapeutic areas.”

Sanofi has considerable expertise in oncology and has increased research and development capabilities, focusing on difficult to treat cancers, including breast, blood, and lung.

Additional terms of the collaboration were not disclosed.

Tags: < Partnership

Related Industries

Health

Supporting the frontlines of Irish healthcare with AWS InCommunities

March 24, 2023
Health

Interview with Mr. Sébastien Huron, CEO, Virbac group

March 6, 2023
Health

Bayer driving innovation in radiology with new research across the portfolio presented at ECR

February 23, 2023
Health

Philips recognized as top innovator for 10th consecutive year

February 17, 2023
Health

Bayer completes acquisition of Blackford Analysis Ltd.

February 14, 2023
Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023

Infineon and UMC extend automotive partnership with long-term agreement for 40nm eNVM microcontroller production

March 8, 2023

...

Aramco and Linde Engineering to develop ammonia cracking technology

March 16, 2023

...

Carrier Makes Donation to the European Food Banks Federation to Help Reduce Food Insecurity in Europe

March 8, 2023

...

TÜV SÜD APPOINTS GERALD BACHLER AS NEW CEO OF THE CENTRAL & EASTERN EUROPE (CEE) REGION

March 2, 2023

...

Huawei’s Green Target Network and 5G Smart Ocean Projects Win Multiple GTI Awards

March 4, 2023

...

EY and IBM Collaborate to Address Complex ESG Challenges and Drive Value-Led Sustainability

March 9, 2023

...

BASF advances innovation pipeline with integrated solutions to accelerate agriculture’s transformation

March 16, 2023

...

Schneider Electric investing €40 million in new smart factory in Hungary

March 23, 2023

...

Supporting the frontlines of Irish healthcare with AWS InCommunities

March 24, 2023

...

Introducing the Aygo X UNDERCOVER

March 3, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist